# Dasatinib in Relapsed or Refractory Non-Hodgkin's Lymphoma

> **NCT00550615** · PHASE1,PHASE2 · COMPLETED · sponsor: **University of Nebraska** · enrollment: 38 (actual)

## Conditions studied

- Non-Hodgkin's Lymphoma

## Interventions

- **DRUG:** Dasatinib
- **DRUG:** Dasatinib Maximum Tolerated Dose

## Key facts

- **NCT ID:** NCT00550615
- **Lead sponsor:** University of Nebraska
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-09-17
- **Primary completion:** 2016-08-01
- **Final completion:** 2017-12-01
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2023-09-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00550615

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00550615, "Dasatinib in Relapsed or Refractory Non-Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00550615. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*